[go: up one dir, main page]

WO2011057220A9 - Compositions et méthodes pour traiter les lymphomes - Google Patents

Compositions et méthodes pour traiter les lymphomes Download PDF

Info

Publication number
WO2011057220A9
WO2011057220A9 PCT/US2010/055876 US2010055876W WO2011057220A9 WO 2011057220 A9 WO2011057220 A9 WO 2011057220A9 US 2010055876 W US2010055876 W US 2010055876W WO 2011057220 A9 WO2011057220 A9 WO 2011057220A9
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating lymphoma
lymphoma
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/055876
Other languages
English (en)
Other versions
WO2011057220A2 (fr
Inventor
Leo I. Gordon
Andrew Evens
Linda Pestano
Kerry Fowler
Scott Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Cascadian Therapeutics Inc
Original Assignee
Northwestern University
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University, Oncothyreon Inc filed Critical Northwestern University
Publication of WO2011057220A2 publication Critical patent/WO2011057220A2/fr
Publication of WO2011057220A9 publication Critical patent/WO2011057220A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2010/055876 2009-11-09 2010-11-08 Compositions et méthodes pour traiter les lymphomes Ceased WO2011057220A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25939609P 2009-11-09 2009-11-09
US61/259,396 2009-11-09
US26678309P 2009-12-04 2009-12-04
US61/266,783 2009-12-04

Publications (2)

Publication Number Publication Date
WO2011057220A2 WO2011057220A2 (fr) 2011-05-12
WO2011057220A9 true WO2011057220A9 (fr) 2011-08-18

Family

ID=43970820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/055876 Ceased WO2011057220A2 (fr) 2009-11-09 2010-11-08 Compositions et méthodes pour traiter les lymphomes

Country Status (1)

Country Link
WO (1) WO2011057220A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399626B2 (en) 2011-11-11 2016-07-26 Pfizer Inc. 2-thiopyrimidinones

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907977A1 (fr) * 2013-04-09 2014-10-16 Mankind Research Centre Intermediaires de n-haloalkylindoline, leur procede et leur utilisation dans la preparation de silodosine et de ses derives
MX382097B (es) 2015-05-05 2025-03-13 Pfizer 1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, y el uso del mismo para tratar afecciones cardiovasculares.
CN112843038B (zh) * 2021-03-30 2022-05-20 徐州医科大学 一种药物在制备治疗弥漫大b细胞淋巴瘤药物中的应用
CN114057668B (zh) * 2021-12-21 2023-08-25 马鞍山诺恩特医药科技有限公司 一种氨基保护基手性2-氨基-3-(4-吗啉基苯基)丙酸的合成方法
CN116370449B (zh) * 2023-03-27 2023-09-15 中国科学院水生生物研究所 一种小分子抑制剂px478在鱼类抗病毒中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399626B2 (en) 2011-11-11 2016-07-26 Pfizer Inc. 2-thiopyrimidinones

Also Published As

Publication number Publication date
WO2011057220A2 (fr) 2011-05-12

Similar Documents

Publication Publication Date Title
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
WO2010123759A9 (fr) Compositions et procédés pour traiter des brûlures
IL218987A0 (en) Methods and compositions for treating cancer
WO2011056650A9 (fr) Méthodes et compositions utilisées dans le cadre du traitement et de la prévention d'infections virales
EP2419670B8 (fr) Procédé de distribution et compositions
EP2429584A4 (fr) Procédés et compositions de traitement
EP2475632A4 (fr) Composés de monochlorotrifluoropropène et compositions et procédés associés
ZA201101055B (en) Compositions and methods for treating osteoarthritis
LT2561067T (lt) Raav-guanilato ciklazės kompozicijos ir būdai, skirti leberio įgimtosios amaurozės-1 (lca1) gydymui
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2355660A4 (fr) Compositions et procédés pour traiter une sclérose en plaques
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL216146A0 (en) Methods and compositions for treating lupus
EP2340254B8 (fr) Compositions et procédés pour traiter l épilepsie
EP2294199A4 (fr) Compositions et procédés pour améliorer des plantes
WO2011057220A9 (fr) Compositions et méthodes pour traiter les lymphomes
ZA201305497B (en) Methods and compositions for preventing and treating osteoarthritis
EP2512504A4 (fr) Composition et méthode thérapeutique
IL217764A0 (en) Methods and compositions for treating leukemia
WO2012057895A9 (fr) Composition et méthode de traitement de lésions
PH12012500528A1 (en) Compositions and methods for treating bacterial infections using caftaroline
EP2537031A4 (fr) Compositions et méthodes pour le traitement du cancer
HK1166283A (en) Methods and compositions for treating leukemia
HK1168281A (en) Methods and compositions for treating lupus
HK1164745A (en) Methods and compositions for treating neuropathies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10829251

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10829251

Country of ref document: EP

Kind code of ref document: A2